3 Healthcare Stock Stories To End the Trading Week

Novartis (NYSE:NVS): Closing price $70.72

The Novartis drug Lucentis has been approved in the European Union as the first effective anti-VEGF treatment for myopic choroidal neovascularization. Lucentis (ranibizumab) represents the first licensed therapy to improve vision in patients suffering with visual impairment because of choroidal neovascularization secondary to pathologic myopia. A pivotal trial indicates average visual acuity improvement of as much as 14 letters at one year with a median of only two injections with Lucentis treatment. Myopic CNV, which is a growth of abnormal leaky blood vessels in the back of the eye in high myopia, often leads to irreversible deterioration of central vision.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

NVS

CorMedix (NYSE: CRMD): Current price $1.18

On Friday, CorMedix said that it has received CE Mark approval for Neutrolin, a catheter lock solution for patients having central venous catheters on hemodialysis secondary to advanced chronic kidney disease. The Neutrolin solution contains an anti-coagulant and broad-spectrum antimicrobial (antibacterial and antifungal) combination which is active against common microbes such as antibiotic-resistant strains, and also inhibits the formation of biofilm. Neutrolin has been proven, as a catheter lock solution, to significantly lower the incidence of catheter-related bloodstream infections, along with maintaining catheter patency by inhibiting thrombosis, thus lowering the necessity for systemic antibiotics and prolonging central venous catheter life.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CRMD

Theragenics Corporation (NYSE:TGX):Closing price $2.03

On Friday, the medical device company serving the surgical products and prostate cancer treatment markets reported that it has signed a supply and reseller accord with Accelyon Limited. Under the three-year arrangement, Theragenics will provide its AgX100 seeds to Accelyon, which will allow the loading and packaging of the seeds into prescription loaded needles, custom strands, and other configurations. For its part, Accelyon will distribute the finished products in the European Union, Australia and New Zealand.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

TGX

Investing Insights: Can General Electric Power Your Portfolio?

More Articles About:    

More from The Cheat Sheet